Anti-
VEGF-A monoclonal antibodies, in combination with
chemotherapy, result in a survival benefit in patients with metastatic colorectal and
non-small cell lung cancer, but little is known regarding the impact of anti-
VEGF-A therapy on benign or premalignant
tumors. The Apc+/min mice have been widely used as a model recapitulating early intestinal
adenoma formation. To investigate whether
tumor growth in Apc+/min mice is mediated by
VEGF-A-dependent angiogenesis, we used two independent approaches to inhibit
VEGF-A: monotherapy with a
monoclonal antibody (Mab) targeting
VEGF-A and genetic deletion of
VEGF-A selectively in intestinal epithelial cells. Short-term (3 or 6 weeks) treatment with anti-
VEGF-A Mab G6-31 resulted in a nearly complete suppression of
adenoma growth throughout the small intestine. Growth inhibition by Mab G6-31 was associated with a decrease in vascular density. Long-term (up to 52 weeks) treatment with Mab G6-31 led to a substantial increase in median survival. Deletion of
VEGF-A in intestinal epithelial cells of Apc+/min mice yielded a significant inhibition of
tumor growth, albeit of lesser magnitude than that resulting from Mab G6-31 administration. These results establish that inhibition of
VEGF-A signaling is sufficient for
tumor growth cessation and confers a long-term survival benefit in an intestinal
adenoma model. Therefore,
VEGF-A inhibition may be a previously uncharacterized strategy for the prevention of the angiogenic switch and growth in intestinal
adenomas.